Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of $114.12 million. The enterprise value is $100.58 million.
Important Dates
The last earnings date was Thursday, March 26, 2026, before market open.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Innate Pharma has 92.25 million shares outstanding. The number of shares has increased by 10.54% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 92.25M |
| Shares Change (YoY) | +10.54% |
| Shares Change (QoQ) | +6.11% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 1.34% |
| Float | 62.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.79 |
| Forward PS | 8.04 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27
| Current Ratio | 1.27 |
| Quick Ratio | 1.27 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -38.85% |
| Return on Invested Capital (ROIC) | -165.88% |
| Return on Capital Employed (ROCE) | -207.17% |
| Weighted Average Cost of Capital (WACC) | 5.85% |
| Revenue Per Employee | $60,764 |
| Profits Per Employee | -$331,838 |
| Employee Count | 174 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.35% in the last 52 weeks. The beta is 0.54, so Innate Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -35.35% |
| 50-Day Moving Average | 1.60 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 38.54 |
| Average Volume (20 Days) | 22,259 |
Short Selling Information
The latest short interest is 76,183, so 0.09% of the outstanding shares have been sold short.
| Short Interest | 76,183 |
| Short Previous Month | 99,192 |
| Short % of Shares Out | 0.09% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.48 |
Income Statement
In the last 12 months, Innate Pharma had revenue of $10.57 million and -$57.74 million in losses. Loss per share was -$0.65.
| Revenue | 10.57M |
| Gross Profit | -40.64M |
| Operating Income | -63.41M |
| Pretax Income | -57.74M |
| Net Income | -57.74M |
| EBITDA | -61.79M |
| EBIT | -63.41M |
| Loss Per Share | -$0.65 |
Full Income StatementBalance Sheet
The company has $40.28 million in cash and $26.50 million in debt, with a net cash position of $13.78 million or $0.15 per share.
| Cash & Cash Equivalents | 40.28M |
| Total Debt | 26.50M |
| Net Cash | 13.78M |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | -25.48M |
| Book Value Per Share | -0.28 |
| Working Capital | 11.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$61.94 million and capital expenditures -$164,377, giving a free cash flow of -$61.22 million.
| Operating Cash Flow | -61.94M |
| Capital Expenditures | -164,377 |
| Depreciation & Amortization | 1.60M |
| Net Borrowing | -10.31M |
| Free Cash Flow | -61.22M |
| FCF Per Share | -$0.66 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -599.77% |
| Pretax Margin | -546.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.54% |
| Shareholder Yield | -10.54% |
| Earnings Yield | -50.60% |
| FCF Yield | -53.65% |
Analyst Forecast
The average price target for Innate Pharma is $5.75, which is 349.22% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.75 |
| Price Target Difference | 349.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 80.55% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innate Pharma has an Altman Z-Score of -11.09 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -11.09 |
| Piotroski F-Score | 1 |
